Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
Status:
Completed
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
The study is a double-blinded, randomized, placebo-controlled, 26-weeks clinical trial. The
objective of the trial is to investigate the effects of the GLP-1 receptor agonist Bydureon®
(exenatide) vs. placebo on alcohol intake in patients with a diagnosis of alcohol dependence.
Phase:
Phase 2
Details
Lead Sponsor:
Anders Fink-Jensen, MD, DMSci
Collaborators:
Neurobiology Research Unit, Rigshospitalet, Copenhagen Section of Biostatistics University of Copenhagen, Copenhagen The Novavì outpatient clinics, Copenhagen